Sentynl Therapeutics receives marketing authorization for Nulibry from UK MHRA
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
A game changing solution for the pharmaceutical industry
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Subscribe To Our Newsletter & Stay Updated